Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frances Shanahan

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Cell Cycle (Georgetown, Tex.)|January 30, 2009
Replication stress activates DNA polymerase alpha-associated Chk1Lorena Taricani, Frances Shanahan, David Parry
Molecular and Cellular Biology|December 16, 2003
Role for BRG1 in cell cycle control and tumor suppressionKristin B Hendricks, Frances Shanahan, Emma Lees
Plos One|November 7, 2014
A functional approach reveals a genetic and physical interaction between ribonucleotide reductase and CHK1 in mammalian cellsLorena Taricani, Frances Shanahan, Maria-Christina Malinao, et al.
Cell Cycle (Georgetown, Tex.)|December 7, 2010
Phenotypic enhancement of thymidylate synthetase pathway inhibitors following ablation of Neil1 DNA glycosylase/lyaseLorena Taricani, Frances Shanahan, Rob H Pierce, et al.
ACS Chemical Biology|December 27, 2023
Allosteric Inhibitors of the SARS-COV-2 Papain-like Protease Domain Induce Proteasomal Degradation of Its Parent Protein NSP3Peter E Cockram, Benjamin T Walters, Aaron Lictao, et al.
Cancers|August 29, 2024
Computational Modeling of Drug Response Identifies Mutant-Specific Constraints for Dosing panRAF and MEK Inhibitors in MelanomaAndrew Goetz, Frances Shanahan, Logan Brooks, et al.
Biorxiv : the Preprint Server for Biology|August 16, 2024
Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanomaAndrew Goetz, Frances Shanahan, Logan Brooks, et al.
Molecular Cancer Therapeutics|February 16, 2011
Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screeningTimothy J Guzi, Kamil Paruch, Michael P Dwyer, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2007
Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitorsMichael P Dwyer, Kamil Paruch, Carmen Alvarez, et al.
Bioorganic & Medicinal Chemistry|March 5, 2014
The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitorsMarc A Labroli, Michael P Dwyer, Ruichao Shen, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Cell Cycle (Georgetown, Tex.)|January 30, 2009
Replication stress activates DNA polymerase alpha-associated Chk1Lorena Taricani, Frances Shanahan, David Parry
Molecular and Cellular Biology|December 16, 2003
Role for BRG1 in cell cycle control and tumor suppressionKristin B Hendricks, Frances Shanahan, Emma Lees
Plos One|November 7, 2014
A functional approach reveals a genetic and physical interaction between ribonucleotide reductase and CHK1 in mammalian cellsLorena Taricani, Frances Shanahan, Maria-Christina Malinao, et al.
Cell Cycle (Georgetown, Tex.)|December 7, 2010
Phenotypic enhancement of thymidylate synthetase pathway inhibitors following ablation of Neil1 DNA glycosylase/lyaseLorena Taricani, Frances Shanahan, Rob H Pierce, et al.
ACS Chemical Biology|December 27, 2023
Allosteric Inhibitors of the SARS-COV-2 Papain-like Protease Domain Induce Proteasomal Degradation of Its Parent Protein NSP3Peter E Cockram, Benjamin T Walters, Aaron Lictao, et al.
Cancers|August 29, 2024
Computational Modeling of Drug Response Identifies Mutant-Specific Constraints for Dosing panRAF and MEK Inhibitors in MelanomaAndrew Goetz, Frances Shanahan, Logan Brooks, et al.
Biorxiv : the Preprint Server for Biology|August 16, 2024
Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanomaAndrew Goetz, Frances Shanahan, Logan Brooks, et al.
Molecular Cancer Therapeutics|February 16, 2011
Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screeningTimothy J Guzi, Kamil Paruch, Michael P Dwyer, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2007
Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitorsMichael P Dwyer, Kamil Paruch, Carmen Alvarez, et al.
Bioorganic & Medicinal Chemistry|March 5, 2014
The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitorsMarc A Labroli, Michael P Dwyer, Ruichao Shen, et al.
Pageof 3